临床试验/jRCT2032260361

jRCT2032260361招募中不适用

An Investigator-initiated trial to assess a long-term safety and efficacy of scleral lens (AL-01) in subjects with corneal astigmatism enrolled in the previous SLICK study (SLICK-extension)

未提供0 个研究点目标入组 25 人开始时间: 待定

适应症

试验速览

阶段: 不适用
状态: 招募中
入组人数: 25

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Single Arm Study

入排标准

年龄范围: 18age old over 至 No limit（—）
性别: All

入选标准

•Signed informed consent must be obtained prior to participation in the study.
•Subjects who have completed the protocol-specified observations in the previous study of AL-
•Subjects for whom the investigator expects continued clinical benefit from wearing AL-01.

排除标准

•Subjects with acute or subacute inflammation or infection in the study eye
•Subjects with uveitis in the study eye
•Subjects with a history of corneal transplant in the study eye
•Pregnant, in postpartum or intends to become pregnant within the study period
•Subjects with corneal opacity and which have no potential for vision improvement with corrective lenses
•Subjects with intermediate media opacities (e.g., moderate to severe cataract or vitreous opacities) or obvious retinal diseases, and which cause vision impairment
•Subjects with ocular complications of Stevens-Johnson syndrome or toxic epidermal necrolysis

研究者

发起方

未提供

相似试验

Safety Evaluation Study of Pitavastatin PLGA nano-particle for Retinitis Pigmentosa (RP CLARITI trial)Retinitis Pigmentosa

jRCT207126000621

Investigator-Initiated Phase II Clinical Trial of MA-5 for Mitochondrial Disease An Exploratory, Investigator-Initiated Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MA-5 in Patients with Mitochondrial Disease and Hearing LossMitochondrial disease with hearing loss

jRCT203125050515

Phase II Investigator-Initiated Clinical Trial of Pitavastatin Therapy for MyelofibrosisMyelofibrosis (MF)

jRCT207126005924

A Phase II Investigator-Initiated Clinical Trial Evaluating the Efficacy and Safety of Combination Therapy with a PAI-1 Inhibitor (TM5614) and Immune Checkpoint Inhibitor Consolidation Therapy following Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (TM-Alliance study) (TM-Alliance study)non-small cell lung cancer

jRCT206126000127

jRCT205226004912